- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Marijuana Doctors's Direct-to-Consumer Weed
A milestone of sorts took place on Monday March 3 when MarijuanaDoctors.com began airing a television commercial that looks to be the first ever marijuana commercial on a major TV network.
A milestone of sorts took place on Monday March 3 when MarijuanaDoctors.com began airing a television commercial that looks to be the first ever marijuana commercial on a major TV network. The spot began airing in New Jersey and is believed to be the first time that any major television network in the U.S. has allowed a commercial addressing the controversial subject matter and advertising the first ever medical marijuana service.
Major networks under the umbrella of Comcast - FOX, Food Network, and Bravo FX etc - have given the commercial the green light.
It wasn’t an easy launch: “Securing the airtime for our commercial on a major network was extremely difficult and at the same time, extremely satisfying,” stated Jason Draizin, Founder and CEO of MarijuanaDoctors.com, Inc.
He added: “The goal of MarijuanaDoctors.com is to bridge that gap between the patients who have a need for marijuana recommendations, and the doctors who write medical marijuana recommendations.” The company allows patients to fill out a form on their website to find a certified physician near their location.
The curious comparison in the commercial has a shady street dealer trying to push tainted sushi on an unsuspecting buyer and medical marijuana patients similarly forced to obtain their weed from the street. Hard to make the leap between an off-tuna roll (or that there even is such a thing as a sushi dealer) and bad pot, but the parallel was drawn in an attempt to prove the severity of consulting physicians in order to obtain medical marijuana for terminal and debilitating medical conditions, rather than reporting to illegal means.
“We felt the viewing public would agree that in the states providing safe access, continuing to obtain medicine illegally is as absurd as purchasing raw fish from a drug dealer,” concluded Draizin.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
